The Government Accountability Office has reported fraudulent Medicaid claims by providers and Medicaid beneficiaries.
A new report from the Government Accountability Office (GAO) says that Medicaid payed millions of dollars for claims filed in the names of deceased beneficiaries. The report has released information from the latest analysis on claims data for the year 2011 from 4 states: Arizona, Florida, Michigan, and New Jersey, which accounted for 13% of Medicaid payments that year.
The report found:
Subsequent to this report, GAO recommends that CMS issue guidance for screening deceased beneficiaries and supply more exhaustive data to better screen Medicaid providers.
Read the complete report: http://1.usa.gov/1PT765K
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More